CT186 / 14 - A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors,
This trial is due to present at the AACR 24 in the same segment as CF33- NHIS, it's been around a while and very much a competitor,
also of interest when you look up the presentation about CF33 no Yuman or Chong on the list. P Woodard and J Byon seem the senior ones.
Clinical trial abstracts are under embargo and will be released at 3:00 PM ET on Friday, April 5.
CT186 / 14 - A first-in-human phase 1 dose-escalation and...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
0.003(3.80%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.4¢ | 7.9¢ | $1.166M | 14.18M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 409605 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 787931 | 5 |
View Market Depth
| Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
|
Last
8.3¢ |
Change
0.003 ( 4.93 %) |
||||
| Open | High | Low | Volume | ||
| 8.0¢ | 8.4¢ | 8.0¢ | 4842402 | ||
| Last updated 15.59pm 29/04/2024 ? | |||||
| IMU (ASX) Chart |